These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 32441324)
1. Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TILs) to treat malignant melanoma: the dawn of a chimeric antigen receptor T (CAR-T) cell therapy from autologous donor. Roncati L; Palmieri B Int J Dermatol; 2020 Jul; 59(7):763-769. PubMed ID: 32441324 [TBL] [Abstract][Full Text] [Related]
2. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115 [TBL] [Abstract][Full Text] [Related]
3. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018 [TBL] [Abstract][Full Text] [Related]
4. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma. Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267 [TBL] [Abstract][Full Text] [Related]
5. Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Sukari A; Abdallah N; Nagasaka M Crit Rev Oncol Hematol; 2019 Apr; 136():1-12. PubMed ID: 30878123 [TBL] [Abstract][Full Text] [Related]
6. Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. Forsberg EMV; Riise R; Saellström S; Karlsson J; Alsén S; Bucher V; Hemminki AE; Olofsson Bagge R; Ny L; Nilsson LM; Rönnberg H; Nilsson JA Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765608 [TBL] [Abstract][Full Text] [Related]
7. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy. Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316 [TBL] [Abstract][Full Text] [Related]
8. Is antigen specificity the key to efficient adoptive T-cell therapy? Labarriere N; Khammari A; Lang F; Dreno B Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191 [TBL] [Abstract][Full Text] [Related]
9. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Burns WR; Zhao Y; Frankel TL; Hinrichs CS; Zheng Z; Xu H; Feldman SA; Ferrone S; Rosenberg SA; Morgan RA Cancer Res; 2010 Apr; 70(8):3027-33. PubMed ID: 20395199 [TBL] [Abstract][Full Text] [Related]
10. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS PLoS One; 2010 Nov; 5(11):e13940. PubMed ID: 21085676 [TBL] [Abstract][Full Text] [Related]
11. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Phan GQ; Rosenberg SA Cancer Control; 2013 Oct; 20(4):289-97. PubMed ID: 24077405 [TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028 [TBL] [Abstract][Full Text] [Related]
13. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. Aebersold P; Hyatt C; Johnson S; Hines K; Korcak L; Sanders M; Lotze M; Topalian S; Yang J; Rosenberg SA J Natl Cancer Inst; 1991 Jul; 83(13):932-7. PubMed ID: 2067036 [TBL] [Abstract][Full Text] [Related]
14. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Svane IM; Verdegaal EM Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366 [TBL] [Abstract][Full Text] [Related]
15. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537 [TBL] [Abstract][Full Text] [Related]
17. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245 [TBL] [Abstract][Full Text] [Related]
18. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Jespersen H; Lindberg MF; Donia M; Söderberg EMV; Andersen R; Keller U; Ny L; Svane IM; Nilsson LM; Nilsson JA Nat Commun; 2017 Sep; 8(1):707. PubMed ID: 28955032 [TBL] [Abstract][Full Text] [Related]
19. Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. Ollé Hurtado M; Wolbert J; Fisher J; Flutter B; Stafford S; Barton J; Jain N; Barone G; Majani Y; Anderson J PLoS One; 2019; 14(8):e0216373. PubMed ID: 31398192 [TBL] [Abstract][Full Text] [Related]